| Scientific Name |
Brolucizumab
|
|---|---|
| Brand Name |
Beovu
|
| Risk |
Discontinue treatment with Beovu in patients who develop events of retinal vasculitis (RV) and/or retinal vascular occlusion (RO).
|
| Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals |
|
| Educational Materials for Patients |
|